« Back
Home /
(S)-RLY-2608

(S)-RLY-2608

Item no.	HY-153306A-1mg
Manufacturer	MedChem Express
CASRN	2733573-93-6
Amount	1 mg
Quantity options	100 mg 10 mg 1 mg 25 mg 50 mg 5 mg
Specific against	other
Citations	[1]Andreas Varkaris, et al. Discovery and clinical proof-of-concept of RLY-2608, a first-in-class mutant-selective allosteric PI3Ka inhibitor that decouples anti-tumor activity from hyperinsulinemia. Cancer Discov. 2023 Nov 2.
Smiles	O=C1N[C@H](C2=CC(F)=CC=C2Cl)C(C1=C3)=C(NC(C4=CC(F)=CC(C(F)(F)F)=C4)=O)C=C3C5=C(C#N)N6C(C=C5)=NC=N6
Shipping condition	Room temperature
Available
Manufacturer - Type	Reference compound
Manufacturer - Targets	Drug Isomer; PI3K
Shipping Temperature	Room temperature
Molecular Weight	608.91
Product Description	(S)-RLY-2608 is an S-enantiomer of of RLY-2608 (HY-153306). RLY-2608 is an orally active first-in-class allosteric mutant-selective inhibitor of PI3Ka with anti-tumor activity [1] .
Manufacturer - Research Area	Cancer
Manufacturer - Pathway	Others; PI3K/Akt/mTOR
Clinical information	No Development Reported

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

Request safety datasheet

Simple Order Order Subscription

Amount: 1 mg

available

Request delivery time